Tagged with Regulation,

association The CEO of Morocco’s oldest pharma association discusses the latest regulatory changes in Morocco and their impact on its members, as well as the position of Moroccan pharma in the African and European context. You have significant experience in the pharmaceutical industry in Morocco. What have been the key steps…

access The general manager of Iberma discusses the history of the Moroccan pharmaceutical industry, new measures to improve access, and working on Moroccan-European partnerships in the pharma sector. You have a long experience of the Moroccan pharmaceutical industry. What have been the most significant changes throughout its history? Morocco initiated its…

regulation Thanks to the recognition COFEPRIS received from the Pan-American Health Organization as national regulatory authority of regional reference, Mexican manufacturers are increasingly eyeing foreign markets to grow. The general manager discusses its objective of transforming Liomont in a global company, the strategic alliances the Mexican manufacturer completed recently as well…

access Healthcare should not be seen as an expenditure, but rather as an investment. Mexico’s former minister of health and current dean at the Harvard T.H. Chan School of Public Health discusses how Mexico is moving towards effective universal coverage, the challenges the system is facing and the issues that remain.…

regulation The general manager of Algeria’s pharmaceuticals regulator narrates the founding and evolution of the institution, how it has been flexing its muscles with the withdrawal of no less than 17 products from the local market, and how the body has been selected to play a leading role in the WHO’s Expert Advisory Panel on…

IP Alicia Alvarez Berkenwald, Partner at the specialized intellectual property services firm Berken IP, gives an introduction to the Argentinian IP environment, common strategies used to bypass obstacles, and Berken IP’s role in helping increase IP awareness in Argentinian research institutions.   Could you give us an overview of the changes…

Novo Nordisk The global COO of the multinational at the forefront of the fight against diabetes explains why the Algerian market is so strategically important and how the ‘made in Algeria’ brand would have real potential at the regional level if only the government would remove impediments to export. As COO of Novo…

doing business Insights from existing players on what to expect and how to succeed in Algeria today. “The key to being successful is to be direct and forthright with the Algerians themselves. Trust in them and they will certainly trust in you.” – Essam Farouk, CEO, El Kendi. “The pace of doing…

CNS Oh Pil-Soo, managing director of Lundbeck Korea, talks about the challenges of pricing and reimbursement in the CNS area and remaining committed to Korea in terms of clinical research.   What have been some of the biggest successes in the last three to four years for this affiliate? The greatest…

generics  Miriam Martinez, CEO of Laboratorios Duncan and VP of CAPGEN, discusses the challenges her company faces as a generic manufacturer in a branded generic market and their plans for growth in the future.   You are currently the Vice President of CAPGEN; could you please tell us a bit about…

innovation Brian Gladsden was appointed president of Novartis Korea in January 2014. He relates his previous experience to the market situation in Korea and highlights the importance of commitment to innovation and working in tandem with the local ecosystem to provide the best access to Korean patients.   You have had…

Boston Consulting Group The managing director of Boston Consulting Group Malaysia discusses the gap between public and private healthcare in the country, and what can be done to bridge it.   What appears to be a focus for many companies now is bridging the gap between the private healthcare sector and the public…